what is the drug semaglutide Ozempic® (semaglutide) GLP-1 RA for Type 2 Diabetes FDA approves obesity drug that
Description
The landmark SURMOUNT-5 trial compared the two drugs directly over 72 weeks: On paper, tirzepatide wins on raw weight loss
Studies in the American Journal of Clinical Nutrition have shown that GLP-1 agonists reduce fasting insulin levels by 2030% in people with insulin resistance, potentially easing hormonal dysfunction rooted in glucose dysregulation
FDA approval is expected in 2027 or 2028
With that, the organization is more likely to see extreme cases of eye health issues, which can skew the study population a bit
Ghrelin is a physiological mediator of feeding and acts through neuropeptide Y and agouti-related protein in the hypothalamus
Start your 14 day free trial today
